Severe ifosfamide-induced neurotoxicity: a case report

被引:0
|
作者
Sara Ramos Linares
Joaquín Breña Atienza
Matilde Cháfer Rudilla
Pablo Ríos Rull
Ana Cabello Rodríguez
Javier Merino Alonso
机构
[1] Hospital Universitario Nuestra Señora de Candelaria,Pharmacy Department
[2] Hospital Universitario Nuestra Señora de Candelaria,Hematology Department
来源
Pharmacy World & Science | 2010年 / 32卷
关键词
Ifosfamide; Neurotoxicity; Risk factors; Treatment;
D O I
暂无
中图分类号
学科分类号
摘要
Introduction Ifosfamide is an alkylating agent used in the treatment of several neoplasias. Ifosfamide metabolites accumulation can produce neurotoxicity, which sometimes manifests as a severe clinical picture. Case description We describe the case of a male with a mixed cellularity subtype classical Hodgkin’s lymphoma, treated with ifosfamide after other chemotherapy drugs failure. After the first Ifosfamide cycle, the patient showed severe neurological toxicity that resolved 3 weeks later with supportive therapy. Discussion Among the risk factors described in the literature, our patient had previously received cysplatin chemotherapy, had low albumin serum levels, and had received ifosfamide as a rapid intravenous infusion. The management of the neurotoxicity is symptomatic although some drugs, like methylene blue and albumin, have also been used. Conclusion This case highlights that clinicians should be aware of the possibility of severe neurological toxicity after the administration of ifosfamide and may control the risk factors associated.
引用
收藏
页码:109 / 111
页数:2
相关论文
共 50 条
  • [31] The Use of Continuous Veno-Venous Hemodiafiltration in the Management of Ifosfamide-induced Encephalopathy: A Case Report
    Yeo, Kee Kiat
    HaDuong, Josephine H.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2016, 38 (06) : 489 - 490
  • [32] Ifosfamide-Induced Encephalopathy and Movement Disorder
    Ames, Bethany
    Lewis, Lionel D.
    Chaffee, Sara
    Kim, Julie
    Morse, Richard
    PEDIATRIC BLOOD & CANCER, 2010, 54 (04) : 624 - 626
  • [33] Ifosfamide-induced Encephalopathy With Rapid Response to Thiamine: A Pediatric Case
    Mungen, Eren
    Bajin, Inci Yaman
    Oz, Sibel
    Gunbey, Ceren
    Anlar, Banu
    Aydin, Burca
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2022, 44 (07) : 402 - 404
  • [34] Incidence of ifosfamide-induced neurotoxicity in lymphoma patients receiving fractionated ICE-based chemotherapy
    Chow, H
    Lim, CH
    Ong, W
    Ng, HJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 601S - 601S
  • [35] ACUTE IFOSFAMIDE-INDUCED TUBULAR TOXICITY
    HENEY, D
    LEWIS, IJ
    BAILEY, CC
    LANCET, 1989, 2 (8654): : 103 - 104
  • [36] Ifosfamide-induced nonconvulsive status epilepticus
    Bhardwaj, A
    Badesha, PS
    ANNALS OF PHARMACOTHERAPY, 1995, 29 (12) : 1237 - 1239
  • [37] Trifluoperazine an Antipsychotic Drug and Inhibitor of Mitochondrial Permeability Transition Protects Cytarabine and Ifosfamide-Induced Neurotoxicity
    Kiani, Amir
    Nik, Shadi Heydari
    Khodadoost, Adineh
    Salimi, Ahmad
    Pourahmad, Jalal
    DRUG RESEARCH, 2020, 70 (06) : 265 - 272
  • [38] IFOSFAMIDE-INDUCED RENAL TUBULAR DEFECTS
    PATTERSON, WP
    KHOJASTEH, A
    CANCER, 1989, 63 (04) : 649 - 651
  • [39] Incidence and severity of ifosfamide-induced encephalopathy
    Rieger, C
    Fiegl, M
    Tischer, J
    Ostermann, H
    Schiel, X
    ANTI-CANCER DRUGS, 2004, 15 (04) : 347 - 350
  • [40] IFOSFAMIDE-INDUCED NONCONVULSIVE STATUS EPILEPTICUS
    WENGS, WJ
    TALWAR, D
    BERNARD, J
    ARCHIVES OF NEUROLOGY, 1993, 50 (10) : 1104 - 1105